Results 51 to 60 of about 38,408 (255)

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates [PDF]

, 1993
Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of Parkinson's disease. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a neurological syndrome in man and non-human primates very ...
Burg, M., Horowski, R., Kalveram, K. T., Lange, Klaus W., Löschmann, P. A., Riederer, Peter, Sofic, E., Wachtel, H.   +7 more
core   +1 more source

Dietary and biomarker‐guided strategies as supportive measures in the fragile X syndrome

Food Biomacromolecules, EarlyView.
Abstract The fragile X syndrome (FXS) is an inherited neurodevelopmental disorder that primarily affects males, often resulting in an IQ below 55, while about two‐thirds of females also experience intellectual disability. Physical features may include an elongated face, prominent ears, finger joint laxity, and enlarged testes in males.
Jailan E. El Halawani, Reem R. AlOlaby
wiley   +1 more source

Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice [PDF]

, 2013
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH).
Arai, Ken, Cianchetti, Flor A., Fan, Xiang, Förch, Christian, Lauer, Arne, Leyen, Klaus van, Lo, Eng H., Mandeville, Emiri, Rosidi, Nathanael L., Schaffer, Chris B., Schlunk, Frieder, Steinmetz, Helmuth, Wang, Xiaoying, Yigitkanli, Kazim   +13 more
core   +6 more sources

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani, Alessandro eStefani, Atticus H Hainsworth, Claudio eLiguori, Enrica eOlivola, Giacoma eAngileri, Mariangela ePierantozzi, Salvatore eGalati, Valentina eSaviozzi, Vincenza eD’Angelo   +9 more
core   +3 more sources

Movement Disorders in Developmental and Epileptic Encephalopathies

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Monogenic developmental and epileptic encephalopathies (DEE) frequently feature co‐occurring movement disorders. Gene discovery has expanded epilepsy‐dyskinesia syndromes (EDS) from classic associations such as stereotypies in Rett syndrome to PRRT2‐related infantile seizures with paroxysmal dyskinesia and crouched gait in SCN1A ...
Shekeeb Mohammad, Darius Ebrahimi‐Fakhari, Hugo Morales‐Briceno   +2 more
wiley   +1 more source

Permissive role for mGlu1 metabotropic glutamate receptors in excitotoxic retinal degeneration [PDF]

, 2017
Neuroprotection is an unmet need in eye disorders characterized by retinal ganglion cell (RGC) death, such as prematurity-induced retinal degeneration, glaucoma, and age-related macular degeneration.
Battaglia, Giuseppe, Beneventano, Martina, Bruno, Valeria, Bucci, Domenico, Di Pietro, Paola, Liberatore, Francesca, Madonna, Michele, Mascio, Giada, Nicoletti, Ferdinando, Puliti, Alda Maria, Romano, Maria Rosaria   +10 more
core   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

NICE 2011 recommendations on the management of Alzheimer’s disease by acetylcholinesterase inhibitors and memantine [PDF]

, 2011
The National Institute of Clinical Excellence (NICE) has lately overturned its decision to restrict the use of acetycholinesterase inhibitors and memantine in patients diagnosed with Alzheimer’s disease (AD).
Scerri, Charles
core  

Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease

Neuroprotection, EarlyView.
In Parkinson's disease (PD) and Alzheimer's disease (AD), various shared pathological mechanisms exist. UDCA has been shown to exert neuroprotective effects in preclinical and clinical studies. Such effects include the mitigation of neuroinflammation as well as rescue effects on mitochondrial dysfunction, oxidative stress, impaired autophagy, and ...
Ashley En Yi Chong, Andrew Octavian Sasmita, Rhun Yian Koh, Anna Pick Kiong Ling   +3 more
wiley   +1 more source

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease [PDF]

, 2012
Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for moderate to severe Alzheimer's disease (AD) treatment within the U.S.
Deshpande, Varun K., Greig, Nigel H., Huang, Xudong, Lahiri, Debomoy K., Olivares, David, Rogers, Jack T., Shi, Ying   +6 more
core   +1 more source